PriceTargets.com logo

CVRx - CVRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $16.67
  • Forecasted Upside: 37.63%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$12.11 As of 12/20/2024 06:16 PM ET
▲ +0.39 (3.33%)

This chart shows the closing price for CVRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CVRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVRX

Analyst Price Target is $16.67
▲ +37.63% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for CVRx in the last 3 months. The average price target is $16.67, with a high forecast of $22.00 and a low forecast of $13.00. The average price target represents a 37.63% upside from the last price of $12.11.

This chart shows the closing price for CVRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 contributing investment analysts is to moderate buy stock in CVRx. This rating has held steady since April 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/9/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$17.00 ➝ $22.00
11/4/2024Craig HallumBoost TargetBuy ➝ Buy$15.00 ➝ $20.00
10/30/2024Lake Street CapitalBoost TargetBuy ➝ Buy$12.00 ➝ $15.00
10/30/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$15.00 ➝ $17.00
10/30/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$13.00 ➝ $16.00
10/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$14.00 ➝ $14.00
9/10/2024Cantor FitzgeraldInitiated CoverageOverweight$14.00
8/26/2024Lake Street CapitalReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
7/30/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$14.00 ➝ $15.00
7/30/2024Piper SandlerLower TargetOverweight ➝ Overweight$15.00 ➝ $13.00
7/11/2024Craig HallumLower TargetBuy ➝ Buy$23.00 ➝ $15.00
7/11/2024Lake Street CapitalLower TargetBuy ➝ Buy$18.00 ➝ $12.00
5/1/2024Lake Street CapitalLower TargetBuy ➝ Buy$35.00 ➝ $18.00
5/1/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$32.00 ➝ $14.00
5/1/2024Piper SandlerLower TargetOverweight ➝ Overweight$33.00 ➝ $15.00
5/1/2024Craig HallumInitiated CoverageBuy$30.00 ➝ $23.00
5/1/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$36.00 ➝ $13.00
5/1/2024William BlairDowngradeOutperform ➝ Market Perform
1/26/2024Piper SandlerBoost TargetOverweight ➝ Overweight$21.00 ➝ $33.00
1/26/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$31.00 ➝ $36.00
12/27/2023Lake Street CapitalBoost TargetBuy ➝ Buy$21.00 ➝ $32.00
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$17.00 ➝ $31.00
7/26/2023Piper SandlerBoost Target$20.00 ➝ $21.00
7/26/2023Lake Street CapitalBoost Target$18.00 ➝ $21.00
5/3/2023Lake Street CapitalBoost Target$15.00 ➝ $18.00
2/10/2023Piper SandlerBoost TargetOverweight$18.50 ➝ $20.00
2/7/2023Canaccord Genuity GroupBoost TargetBuy$22.00 ➝ $23.00
1/31/2023Lake Street CapitalInitiated CoverageBuy$20.00
1/27/2023JPMorgan Chase & Co.Boost TargetOverweight$17.00 ➝ $18.00
1/9/2023Piper SandlerBoost Target$14.00 ➝ $18.50
11/2/2022Piper SandlerBoost TargetOverweight$10.00 ➝ $14.00
7/18/2022Craig HallumInitiated CoverageBuy$15.00
1/13/2022Canaccord Genuity GroupLower Target$30.00 ➝ $17.00
7/26/2021JPMorgan Chase & Co.Initiated CoverageOverweight$24.00
7/26/2021William BlairInitiated CoverageOutperform$20.22
7/26/2021Piper SandlerInitiated CoverageOverweight$26.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.11 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 12 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 10 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

CVRx logo
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $12.11
Low: $11.39
High: $12.28

50 Day Range

MA: $13.07
Low: $7.88
High: $15.83

52 Week Range

Now: $12.11
Low: $6.40
High: $33.13

Volume

299,709 shs

Average Volume

270,166 shs

Market Capitalization

$293.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of CVRx?

The following sell-side analysts have issued reports on CVRx in the last twelve months: Canaccord Genuity Group Inc., Cantor Fitzgerald, Craig Hallum, JPMorgan Chase & Co., Lake Street Capital, Piper Sandler, and William Blair.
View the latest analyst ratings for CVRX.

What is the current price target for CVRx?

0 Wall Street analysts have set twelve-month price targets for CVRx in the last year. Their average twelve-month price target is $16.67, suggesting a possible upside of 37.6%. Canaccord Genuity Group Inc. has the highest price target set, predicting CVRX will reach $22.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $13.00 for CVRx in the next year.
View the latest price targets for CVRX.

What is the current consensus analyst rating for CVRx?

CVRx currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CVRX.

What other companies compete with CVRx?

Other companies that are similar to CVRx include BioLife Solutions, Pulse Biosciences, Artivion, Embecta and CeriBell. Learn More about companies similar to CVRx.

How do I contact CVRx's investor relations team?

The company's listed phone number is 763-416-2840 and its investor relations email address is [email protected]. The official website for CVRx is www.cvrx.com. Learn More about contacing CVRx investor relations.